Evaluation of serum nesfatin-1 levels in polycystic ovarian syndrome women: A cross-sectional case–control study.
DOI:
https://doi.org/10.51168/sjhrafrica.v6i12.2347Keywords:
Polycystic ovarian syndrome, Nesfatin-1, insulin resistance, metabolic parameters, hormonal profileAbstract
Background:
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder associated with metabolic and hormonal disturbances. Nesfatin-1 is emerging as a potential biomarker linked to insulin resistance and ovarian dysfunction.
Objective:
To evaluate serum nesfatin-1 levels in women with PCOS and assess their correlation with clinical, metabolic, and hormonal parameters.
Methods:
This cross-sectional case–control study included 50 women with PCOS and 50 age- and BMI-matched healthy controls. Clinical features, metabolic parameters, and hormonal profiles were assessed. Serum nesfatin-1 levels were measured using ELISA.
Results:
Mean serum nesfatin-1 levels were significantly higher in the PCOS group (6.03 ± 1.58 ng/ml) compared to controls (1.98 ± 1.00 ng/ml). Triglycerides (80.76 ± 12.32 mg/dl) and LDL cholesterol (99.86 ± 9.91 mg/dl) showed positive correlation, while HDL cholesterol showed negative correlation with nesfatin-1 levels. Hormonal parameters, including FSH (7.32 ± 2.92 mIU/ml), LH (6.58 ± 3.81 mIU/ml), and serum insulin (9.71 ± 7.56 µU/ml), were positively correlated with nesfatin-1.
Conclusion:
Serum nesfatin-1 levels are significantly elevated in PCOS women and are associated with metabolic and hormonal disturbances.
Recommendations:
Nesfatin-1 may serve as a useful biomarker for early detection and metabolic risk stratification in PCOS patients.
References
Kohno D, Nakata M, Maejima Y et al (2008) Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 149:1295-1301. https://doi.org/10.1210/en.2007-1276
Brailoiu GC, Dun SL, Brailoiu E et al (2007) Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 148:5088-5094. https://doi.org/10.1210/en.2007-0701
Oh IS, Shimizu H, Satoh T et al (2006) Identification of nesfatin1 as a satiety molecule in the hypothalamus. Nature 443:709-712. https://doi.org/10.1038/nature05162
Gonzalez R, Tiwari A, Unniappan S (2009) Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 381:643-664. https://doi.org/10.1016/j.bbrc.2009.02.104
Yada T, Dezaki K, Sone H et al (2008) Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential. Curr Diabetes Rev 4:18-23. https://doi.org/10.2174/157339908783502352
Meier JJ, Gallwitz B, Schmidt WE et al (2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269-279. https://doi.org/10.1016/S0014-2999(02)01434-6
Nakata M, Manaka K, Yamamoto S et al (2011) Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2? Influx through L-type channels in mouse islet β-cells. Endocr J 58:305-313. https://doi.org/10.1507/endocrj.K11E-056
Stengel A, Goebel M, Yakubov I et al (2009) Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150:232-238. https://doi.org/10.1210/en.2008-0747
Suheyla Gorar Ayse Carlıoglu Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest (2014) 37:715-719. Italian Society of Endocrinology (SIE) 2014. https://doi.org/10.1007/s40618-014-0089-2
Esra Alp1, Uzay Görmüş Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Published online 10 June 2015.
Rulin Deniz • Bilgin Gurates Nesfatin-1 and other hormone alterations in polycystic ovary syndrome Endocrine (2012) 42:694-699. https://doi.org/10.1007/s12020-012-9638-7
Hamed AI, Elsamman AM, Abd Elwahab SM, et al. Serum nesfatin-1 levels in women with polycystic ovary syndrome and their relation to insulin resistance. J Obstet Gynaecol Res. 2022;48(3):642-649.
Wang Y, Zhang X, Li L, et al. Altered nesfatin-1 levels in patients with polycystic ovary syndrome and its association with metabolic parameters. Gynecol Endocrinol. 2021;37(6):517-522.
Sahin FK, Sahin SB, Ural UM, et al. Nesfatin-1 levels and cardiovascular risk parameters in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2015;82(5):671-677.
Mangalath AS, Gopalakrishnan S, Jayasree AK. Prevalence and determinants of polycystic ovary syndrome among reproductive-age women in urban and rural areas of South India. Int J Reprod Contracept Obstet Gynecol. 2018;7(2):492-498.
Sarkar P, Gupta P, Basu S. Lifestyle factors influencing prevalence of polycystic ovary syndrome in urban women. Indian J Endocrinol Metab. 2006;10(2):78-84.
Dhagat S, Patel M, Shah S. Clinical profile and infertility patterns in women with polycystic ovarian syndrome. Int J Reprod Biomed. 2017;15(6):375-380.
Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus in polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84(1):165-169. https://doi.org/10.1210/jc.84.1.165 https://doi.org/10.1210/jcem.84.1.5393
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030. https://doi.org/10.1210/er.2011-1034
Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity, and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-637. https://doi.org/10.1093/humupd/dms030
Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement. Hum Reprod. 2009;24(9):2331-2337.
Teede HJ, Misso ML, Costello MF, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. https://doi.org/10.1093/humrep/dey256
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Shilpy Priyadarshani, Shaila Mitra, Ankita Kumari
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
